Cargando…
ISS-N1 makes the First FDA-approved Drug for Spinal Muscular Atrophy
Spinal muscular atrophy (SMA) is one of the leading genetic diseases of children and infants. SMA is caused by deletions or mutations of Survival Motor Neuron 1 (SMN1) gene. SMN2, a nearly identical copy of SMN1, cannot compensate for the loss of SMN1 due to predominant skipping of exon 7. While var...
Autor principal: | Ottesen, Eric W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter Open
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5382937/ https://www.ncbi.nlm.nih.gov/pubmed/28400976 http://dx.doi.org/10.1515/tnsci-2017-0001 |
Ejemplares similares
-
Spinal Muscular Atrophy: The Treatment Approved
por: Tabet, Rabih, et al.
Publicado: (2017) -
The First Orally Deliverable Small Molecule for the Treatment of
Spinal Muscular Atrophy
por: Singh, Ravindra N, et al.
Publicado: (2020) -
Magnetic resonance imaging of the cervical spinal cord in spinal muscular atrophy
por: Stam, Marloes, et al.
Publicado: (2019) -
Bedaquiline: First FDA-approved tuberculosis drug in 40 years
por: Mahajan, Rajiv
Publicado: (2013) -
Celebrating a breakthrough: the first-ever FDA-approved treatment for geographic atrophy: a correspondence
por: Khan, Abdul Moiz, et al.
Publicado: (2023)